Sharing our research across the globe
Professor Sergio Rutella (pictured above, left with his collaborator Dr Jan Davidson-Moncada from Wugen) and the JvGCRC team recently attended the American Society of Haematology’s (ASH) 64th Annual Meeting in New Orleans, Louisiana. They presented data on WU-NK-101, a novel immunotherapy harnessing the power of “memory” natural killer (NK) cells to treat liquid and solid tumours. NK cells normally protect us from infections and have the ability to kill cancer cells.
However, they don’t work properly in acute myelogenous leukaemia (AML). This work was carried out by Professor Sergio Rutella, Dr Jayakumar Vadakekolathu and Dr David Boocock at the JvGCRC, in close collaboration with Wugen, a clinical-stage biotechnology company developing cell therapies to treat a broad range of haematological and solid tumour malignancies. An early-phase clinical trial is due to commence in the USA this year.
|